Allergan And Editas Sharpen Their CRISPR Focus On Ocular Drugs

07 Aug 2018

• By Sten Stovall

Allergan and CRISPR specialist Editas have reinforced their gene editing R&D pact launched in March 2017.

SC1808_Genome Editing_1146082469_1200.jpg — Duo to jointly develop and market EDIT-101 For LCA10 • Source: Shutterstock

More from Business

More from Scrip